FDA-APPROVED PRESCRIPTION DRUG

HGH (Human Growth Hormone / Somatropin)

A prescription hormone medication, not a research peptide. FDA-approved for specific medical conditions. Widely talked about in anti-aging and performance contexts, where the legal and evidence picture looks very different from the clinical one.

Important: HGH is a prescription drug, not a research peptide

Most of the peptides covered on this site are research compounds in legal grey zones. HGH (somatropin) is different, it's an FDA-approved prescription drug, regulated under federal law, and possession or distribution outside a valid prescription is a federal crime in the United States under 21 U.S.C. §333(e). This page explains what HGH is, what it's actually approved for, and why the anti-aging conversation around it doesn't match the evidence.

The 30-second read

HGH is a 191-amino-acid protein hormone that your pituitary gland makes naturally. Recombinant human growth hormone (somatropin) is a lab-made identical copy, sold as FDA-approved prescription drugs like Genotropin, Humatrope, Norditropin, Omnitrope, and others. It's approved for specific medical conditions, pediatric growth failure, adult growth hormone deficiency, AIDS-associated wasting, short-bowel syndrome, Turner syndrome, Prader-Willi syndrome, and a few others. It's also widely used off-label for anti-aging, bodybuilding, and performance, where the evidence is much weaker than the marketing implies, the legal exposure is real, and concerns about IGF-1-related cancer risk haven't been resolved. Federally regulated as a non-controlled prescription drug, but with a special trafficking statute that treats off-label distribution as a federal crime.

Why this is on people's radar

HGH has been in the cultural conversation for decades. The original story is medical: Genentech and Eli Lilly developed recombinant somatropin in the 1980s, replacing the older cadaveric pituitary extracts (which were withdrawn after Creutzfeldt-Jakob disease cases). Recombinant HGH transformed care for children with severe growth disorders and became one of the first major biotech drug success stories.

The anti-aging story is mostly traceable to a single 1990 paper in the New England Journal of Medicine by Daniel Rudman and colleagues, which reported that 12 men in their 60s and 70s, treated with HGH for six months, gained lean mass and lost fat mass. That paper has been cited in popular media and clinic marketing for thirty-plus years as evidence that HGH "reverses aging." The follow-up science has been substantially less impressive: subsequent trials have shown body-composition changes without functional improvements, and the original authors of the Rudman paper later co-signed editorials warning against the way their work was being used.

The performance story is more mainstream than people realize. HGH has been at the center of major doping cases across professional sports (cycling, baseball, football, MMA) for two decades. WADA bans it. Major league sports test for it (imperfectly, since detection is genuinely hard). The cultural footprint of HGH in bodybuilding circles is enormous, and the anti-aging clinic industry built around it is a multi-billion-dollar business in the US, much of it operating in legally questionable territory.

What HGH is used for (clinically and otherwise)

There's a sharp split between approved uses and how HGH is most often discussed online:

  • Approved use: Treating diagnosed growth hormone deficiency in children and adults
  • Approved use: Treating specific genetic and medical conditions (Turner syndrome, Prader-Willi, short-bowel, AIDS wasting, idiopathic short stature meeting criteria)
  • Off-label discussion: Anti-aging, body composition, "feeling younger"
  • Off-label discussion: Bodybuilding, performance, recovery (banned by every major sport)
  • Off-label discussion: Sleep, mood, cognition (very limited evidence)

What the science actually shows

Plain-English summary of the evidence:

For diagnosed growth hormone deficiency, HGH works

In children with confirmed GHD, recombinant somatropin produces meaningful, measurable improvements in height velocity and final adult stature. This is the indication HGH was developed for, and the evidence is solid.1

For adult GHD, body composition and quality-of-life data are real

Adults with documented growth hormone deficiency (typically from pituitary disease, surgery, or radiation) show consistent improvements in body composition, exercise capacity, and several quality-of-life measures with replacement therapy.2

For non-deficient older adults, the picture is much weaker

The body-composition changes reported in Rudman's 1990 NEJM paper have been replicated, but consistent functional improvements (strength, endurance, cognition) generally have not. Side effects in this population (joint pain, fluid retention, insulin resistance, carpal tunnel) are common.3

For athletic performance, evidence is mostly anecdotal

Despite widespread use in bodybuilding and pro sports, controlled trials haven't shown HGH alone reliably improves measurable athletic performance in healthy adults. The body-composition effects are real; the strength and endurance effects are much harder to demonstrate.4

IGF-1 and cancer concerns are unresolved

HGH raises IGF-1 levels. Higher IGF-1 has been associated with increased risk of several cancers in epidemiologic studies. Whether long-term HGH use in non-deficient adults raises cancer risk hasn't been definitively answered, and is a meaningful concern in the literature.5

The honest read

What's solid:

HGH is a legitimate, deeply important medication for children and adults with diagnosed growth hormone deficiency. For those approved indications, the evidence is strong and the clinical experience is decades long.

What's still being worked out:

Whether long-term off-label HGH in non-deficient adults produces meaningful health benefits or whether the body-composition changes come with real functional improvements. The long-term cancer-risk question is also unsettled and matters.

What's hyped beyond the evidence:

The "HGH reverses aging" framing that built the anti-aging clinic industry. The 1990 Rudman paper has been worked harder than any twelve-patient pilot study should have been, and the original investigators themselves later cautioned against this use. Side effects in non-deficient adults are common, the long-term safety picture isn't reassuring, and federal law treats off-label distribution as a serious offense.

Things to know if you're looking into it

  • Federal trafficking statute: Under 21 U.S.C. §333(e), distributing or possessing HGH for any use other than disease treatment authorized by a physician is a federal crime, with penalties up to 5 years in prison (10 if a minor is involved).
  • Prescription-only: HGH is dispensed by licensed pharmacies on physician prescription only. Sources outside that channel, including most anti-aging clinic and "research peptide" sources, operate outside federal law.
  • Banned in sport: WADA, USADA, MLB, NFL, NCAA, and essentially every governing body ban HGH. Detection has improved over the past decade.
  • Documented diagnosis matters: Real GHD diagnosis requires endocrinology workup including stimulation testing. "Low-normal" IGF-1 alone is not GHD, despite what some clinics suggest.
  • Common side effects: joint pain, swelling, carpal tunnel symptoms, insulin resistance, glucose intolerance. More serious risks include diabetes onset and possible cancer-risk concerns long-term.
  • Mechanism, dosing, and references: in the "Want to go deeper?" section below.

What people often ask

Is HGH a peptide?

Technically yes, it's a 191-amino-acid protein hormone, which falls under the broad biochemical umbrella of "peptide" or "polypeptide hormone." Culturally and legally, though, it's a prescription drug, not a research peptide. The other peptides on this site exist mostly in research grey zones; HGH is an approved drug with a federal trafficking statute attached.

Why do anti-aging clinics prescribe it if the evidence is weak?

Off-label prescribing is legal (physicians can prescribe approved drugs for unapproved uses if they judge it appropriate). The challenge is that physicians prescribing HGH for anti-aging often diagnose "adult growth hormone deficiency" using thresholds endocrinology guidelines wouldn't accept, which raises both medical and legal questions. The federal trafficking statute (§333(e)) was specifically written to make distribution for non-disease use a crime even with a "prescription."

What about peptides that increase HGH naturally, like Sermorelin or Ipamorelin?

Growth hormone secretagogues (Sermorelin, Tesamorelin, Ipamorelin, CJC-1295, GHRP-2, GHRP-6, Hexarelin, MK-677) raise endogenous HGH release rather than supplying exogenous HGH. They have different legal and safety profiles. Sermorelin and Tesamorelin are FDA-approved drugs for specific indications. The others are research peptides covered elsewhere on this site.

Is there a real cancer risk?

Higher IGF-1 levels (which HGH raises) are associated with increased risk of several cancers in epidemiologic studies. Whether using HGH long-term increases cancer risk in non-deficient adults isn't definitively answered, but it's a real concern in the medical literature, not a fringe worry.

What are the legitimate brands?

FDA-approved recombinant somatropin products in the US include Genotropin (Pfizer), Humatrope (Lilly), Norditropin (Novo Nordisk), Omnitrope (Sandoz), Saizen (EMD Serono), Zomacton (Ferring), Skytrofa (Ascendis, weekly long-acting), and Sogroya (weekly long-acting). All are dispensed by prescription only.

FDA and regulatory status

Status as of May 5, 2026: Recombinant somatropin is FDA-approved as a prescription drug for specific indications: pediatric growth hormone deficiency, idiopathic short stature meeting criteria, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age children failing to catch up, chronic kidney disease growth failure, adult growth hormone deficiency, AIDS-associated wasting, and short-bowel syndrome. Off-label use (anti-aging, body composition, performance) is not FDA-approved. Federal law under 21 U.S.C. §333(e) makes distribution of HGH for non-disease indications a federal crime. Status updates land here when they happen.

Want to go deeper? Mechanism of action, the GH/IGF-1 axis, and references.

Background

Human growth hormone is a 191-amino-acid single-chain polypeptide produced by the somatotroph cells of the anterior pituitary gland. Secretion is pulsatile, peaks during early sleep, and is regulated by hypothalamic releasing (GHRH, ghrelin) and inhibiting (somatostatin) factors. Recombinant somatropin (1985 onward) has the same 191-amino-acid sequence as native pituitary HGH. Earlier pituitary-derived HGH was withdrawn after several recipients developed Creutzfeldt-Jakob disease.

Mechanism of action

HGH binds the growth hormone receptor (GHR), a transmembrane class I cytokine receptor. Receptor dimerization activates JAK2 kinase, leading to STAT5 phosphorylation and downstream gene transcription. The major systemic mediator of HGH's anabolic effects is IGF-1, produced primarily by the liver in response to GHR activation. Many of HGH's effects on muscle, bone, and metabolism are mediated by IGF-1 acting at IGF-1 receptors in target tissues.

FDA-approved recombinant HGH products

Daily injections: Genotropin (Pfizer), Humatrope (Lilly), Norditropin (Novo Nordisk), Omnitrope (Sandoz), Saizen (EMD Serono), Zomacton (Ferring), Nutropin AQ (Genentech).

Weekly long-acting: Skytrofa / lonapegsomatropin (Ascendis), Sogroya / somapacitan (Novo Nordisk), Ngenla / somatrogon (Pfizer).

Approved-indication dosing

Dosing varies substantially by indication, age, and weight, and is determined by treating endocrinologists. Pediatric GHD typical dosing is roughly 0.16–0.24 mg/kg/week divided across daily injections. Adult GHD typical dosing is much lower and weight- or non-weight-based depending on protocol. Off-label "anti-aging" dosing in clinic settings is variable and not anchored to FDA-approved labels. This site does not provide off-label dosing guidance.

References

  1. Grimberg A, et al. (2016). "Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents." Horm Res Paediatr, 86(6), 361–397. PubMed
  2. Molitch ME, et al. (2011). "Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab, 96(6), 1587–1609. PubMed
  3. Liu H, et al. (2007). "Systematic review: the safety and efficacy of growth hormone in the healthy elderly." Ann Intern Med, 146(2), 104–115. PubMed
  4. Liu H, et al. (2008). "Systematic review: the effects of growth hormone on athletic performance." Ann Intern Med, 148(10), 747–758. PubMed
  5. Renehan AG, et al. (2004). "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis." Lancet, 363(9418), 1346–1353. PubMed
  6. Rudman D, et al. (1990). "Effects of human growth hormone in men over 60 years old." N Engl J Med, 323(1), 1–6. (The much-cited and frequently misused study.) PubMed
  7. Perls TT, Reisman NR, Olshansky SJ. (2005). "Provision or distribution of growth hormone for 'antiaging': clinical and legal issues." JAMA, 294(16), 2086–2090. PubMed
  8. U.S. Food and Drug Administration. "Somatropin Drug Information." FDA.gov
For educational and research purposes only. This is not medical advice. HGH is a prescription drug with significant legal restrictions and side-effect profile; obtaining or using it outside a valid physician prescription is a federal crime in the United States. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.